Metastatic Breast Cancer — A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
Citation(s)
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109